News
Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback